CTPS2

Across TCGA pan-cancer cohorts, CTPS2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CTPS2 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CTPS2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CTPS2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where CTPS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	II,III,IV	0.752	0.340	.001	50	view →
HNSC	OS	Median	II,III,IV	0.938	0.987	.026	7	view →
LUAD	DFS	Median	All	0.465	0.721	.018	7	view →
UCEC	DFS	Median	All	0.951	0.857	.029	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CTPS2–PDAC (OS)

Open the PDAC breakdown →